

Date: 8 April 2022

Re: Freedom of Information Request
Ref: 125-2022

Thank you for your email dated the 7/4/2022, requesting information in relation to melanoma, renal cell carcinoma treatment and advanced/metastatic oesophageal cancer.

The information that you require is as follows:

Q1. In the last 3 months, how many patients have been initiated* on the following agents for treatment for melanoma?

- Nivolumab (monotherapy)
- Nivolumab AND Ipilimumab (combination)

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

This information is exempt under section 22 of the Freedom of Information Act as the Trust intends to publish this information at a future date.

Q2. In the last 3 months, how many patients have been initiated* on the following agents for treatment for Renal Cell Carcinoma?

- Nivolumab (monotherapy)
- Nivolumab + Ipilimumab
- Nivolumab + Cabozantinib
- Avelumab + Axitinib

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

This information has been previously published at:
[Date \(clatterbridgecc.nhs.uk\)](http://clatterbridgecc.nhs.uk)

Q3. In the past 3 months, how many patients have been initiated* on the following agents for treatment for Advanced/Metastatic Oesophageal Cancer:

- Nivolumab (monotherapy)
- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)

This information is exempt under section 22 of the Freedom of Information Act as the Trust intends to publish this information at a future date.

***Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.**

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.

Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY

If you are not satisfied with the outcome of the internal investigation/review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

In order for us to ensure customer satisfaction and to monitor compliance with the Freedom of Information Act 2000, we would be grateful if you could take a couple of minutes to complete a short feedback form via the link below:

<https://www.surveymonkey.co.uk/r/H39RFMM>

Kind Regards,

The Information Governance Team
Contact Email: ccf-tr.foi@nhs.net